Price Target Changes｜Stifel Boosted Twitter from $39 to $54.2
Benzinga2022-04-26
- HC Wainwright & Co. raised Nkarta, Inc. price target from $25 to $36. Nkarta shares fell 7.2% to $17.38 in pre-market trading.
- SVB Leerink cut the price target for Eliem Therapeutics, Inc. from $33 to $13. Eliem Therapeutics shares dipped 55.8% to $2.88 in pre-market trading.
- Raymond James reduced HCA Healthcare, Inc. price target from $275 to $245. HCA Healthcare shares rose 1% to $212.50 in pre-market trading.
- Keybanc lowered the price target on The Middleby Corporation from $220 to $200. Middleby shares gained 0.6% to close at $153.42 on Monday.
- Citigroup raised the price target on American Express Company from $187 to $190. American Express shares fell 0.5% to $183.11 in pre-market trading.
- Stifel boosted the price target on NextDecade Corporation from $2 to $4. NextDecade shares fell 1.7% to $5.96 in pre-market trading.
- Needham raised the price target for Cadence Design Systems, Inc. from $185 to $193. Cadence Design shares rose 3.6% to $156.52 in pre-market trading.
- Piper Sandler reduced Redfin Corporation price target from $40 to $11. Redfin shares fell 5.6% to $12.35 in pre-market trading.
- Tigress Financial increased Snap-on Incorporated price target from $295 to $298. Snap-on shares rose 0.4% to close at $223.26 on Monday.
- Stifel boosted Twitter, Inc. price target from $39 to $54.2. Twitter shares rose 0.5% to $51.98 in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
